The Science of Psychedelics for Mental Health | Dr. Robin Carhart-Harris

Andrew Huberman and Dr. Robin Carhart-Harris trace the science and history of classic psychedelics, from the etymology of the word 'psychedelic' to how psilocybin, LSD, and DMT act on the serotonin 2A receptor to increase global brain connectivity. They detail the structure of psychedelic-assisted therapy sessions (eye masks, music, two facilitators, 'trust, let go, be open') and the strong therapeutic outcomes seen in trials for depression, anorexia, and fibromyalgia. Carhart-Harris explains why microdosing largely failed to beat placebo, why classic psychedelics outperform non-hallucinogenic alternatives, and how the experience itself predicts therapeutic benefit. The conversation also covers ego dissolution, the integration phase, MDMA for PTSD, and the legal/regulatory landscape moving toward FDA approval.

• A citizen-science microdosing study found microdosing did not compellingly beat placebo; belief that you got a dose drove most of the effect.
  00:23:16
• Increased global brain connectivity from psilocybin persists after the trip, seen the next day and three weeks later, correlating with symptom improvement.
  01:00:34
• Carhart-Harris reports over 70% of treatment-resistant depression patients get relief, far above typical antidepressants.
  01:14:15
• A single 25mg psilocybin session produced measurable anatomical brain changes (white matter tract integrity) resembling a younger, developing brain.
  01:24:48
• Pre-trial expectancy predicted response to escitalopram but NOT to psilocybin, undercutting the idea that psychedelic therapy is just a placebo effect.
  01:39:36
• Most treatment-resistant depression patients eventually relapse, and they cannot legally repeat the treatment that worked, which he calls 'a sick joke.'
  02:11:13
• MDMA therapy for PTSD is years ahead of psilocybin; MAPS completed two phase III trials with ~67% remission, with approval possibly this year.
  02:23:22

• The word 'psychedelic' was coined by Humphry Osmond, who beat Aldous Huxley's term, with the ditty 'to fathom hell or soar angelic, just take a pinch of psychedelic.'
  00:07:48
• Roughly 1 gram of magic mushrooms contains about 10 milligrams of psilocybin (~1% by mass).
  00:27:27
• Psychedelic therapy uses eye masks and lyric-free music; the music's emotional role has never been properly tested despite being a staple of every successful trial.
  00:31:10
• The guiding mantra 'trust, let go, be open' is attributed to Bill Richards at Johns Hopkins.
  00:39:33
• In healthy-volunteer trials, a 1mg psilocybin dose is used as a placebo because subjects feel nothing and EEG shows no change.
  01:08:01
• Anorexia nervosa is the most deadly of all psychiatric illnesses; an ongoing psilocybin trial showed improved weight at long follow-up.
  01:11:08
• DMT is described as a 'rocket ship'; it is an order of magnitude less potent than psilocybin but produces wilder experiences at standard doses.
  01:58:07
• A study found cocaine inflates the ego while psychedelics dissolve it, cleanly separating the two drug classes on opposite axes.
  02:07:31
• Fentanyl lacing now shows up in street MDMA and psychedelics, a serious danger for those using uncertain sources.
  02:14:22
• Carhart-Harris argues psychiatric drugs haven't fundamentally improved since the 1950s, making psychedelic therapy a true paradigm shift.
  02:31:16

Books, products and media the guest or host genuinely endorsed here — with the buy link.

Affiliate link — we may earn a commission at no extra cost to you.